Anthony W. Tolcher

Texas Oncology — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

74h-index23.8kcitations933works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(154), Lung Cancer Treatments and Mutations(124), HER2/EGFR in Cancer Research(109), Colorectal Cancer Treatments and Studies(105), Cancer Treatment and Pharmacology(96)

Publications931 total

Phase 1 Study of Rezatapopt, a p53 Reactivator, in <i>TP53</i> Y220C–Mutated Tumors
New England Journal of Medicine·2026· 1 cited
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational <scp>ATRi</scp> Tuvusertib on <scp>QTc</scp> Interval in Patients With Solid Tumors
Clinical and Translational Science·2026Open Access
Phase 1 evaluation of ASP3082, a first-in-class selective protein degrader, in patients (pts) with <i>KRAS G12D</i> -mutant pancreatic ductal adenocarcinoma (PDAC): Pharmacokinetics (PK) and biomarker insights.
Journal of Clinical Oncology·2026
Table S2 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Table S3 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Censoring rules 3 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Table S1 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Methodology and Criteria for MDSCs 2 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Inclusion and Exclusion Criteria 1 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Table S4 from Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
2025Open Access
Supplementary Data 1 from Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
2025Open Access
Supplementary Table S6 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Table S1 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Material 1 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Figure S3 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
2025Open Access
Figure 3 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Table S3 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Figure S4 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
2025Open Access
Figure 2 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
2025Open Access
Supplementary Figure S5 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
2025Open Access
page 1 of 47Next →

Frequent Co-authors

Amita Patnaik(26), Kyriakos P. Papadopoulos(17), Eric K. Rowinsky(9), Drew Rasco(9), Chris H. Takimoto(7), Johann S. de Bono(7), Muralidhar Beeram(6), Garry Schwartz(5), Alain C. Mita(5), Monica Mita(5), Martin Gleave(5), Lisa A. Hammond(4), Theresa A. Mays(4), Andrew Goetz(4), Antoni Ribas(3), Louis Denis(3), Lon Smith(3), Geoffrey I. Shapiro(3), David Olmos(3), Toshio Shimizu(3)